Fremeau Robert Thomas Jr. 4
4 · Vyant Bio, Inc. · Filed Mar 17, 2022
Insider Transaction Report
Form 4
Vyant Bio, Inc.VYNT
Fremeau Robert Thomas Jr.
Chief Scientific Officer
Transactions
- Award
Stock option (right to buy)
2022-03-15+75,000→ 75,000 totalExercise: $1.00Exp: 2032-03-15→ Common Stock (75,000 underlying)
Footnotes (1)
- [F1]The option shall become exercisable with respect to twenty five percent (25%) of the shares underlying the option upon the date of grant, with respect to thirty seven and a half percent (37.5)% upon the filing by the Company of an Investigational New Drug Application ("IND") with the U.S. Food and Drug Administration ("FDA") for a New Chemical Entity ("NCE") candidate to treat Rett Syndrome and with respect to the remaining thirty seven and a half percent (37.5)% upon the filing by the Company of an IND with the FDA for an NCE candidate to treat CDKL5 Deficiency Disorders; provided that the participant remains a service provider to the Company through each applicable vesting date.